Pediatric reference intervals for bone markers

Clinical Biochemistry

Volumn 39, Issue 6, 2006, Pages 561-568

  Yang, Liju ^a   Grey, Vijaylaxmi ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Bone alkaline phosphatase; Bone markers; C telopeptides; Deoxypyridinoline; N telopeptides; Osteocalcin; Pediatric reference intervals; Pyridinoline

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; HYDROXYLYSINE; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN; PYRIDINIUM DERIVATIVE; TELOPEPTIDE;

ANALYTIC METHOD; BIOLOGICAL MONITORING; BLOOD ANALYSIS; BONE; BONE DISEASE; BONE GROWTH; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CHILD GROWTH; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); GROUPS BY AGE; HUMAN; MEASUREMENT; OSSIFICATION; OSTEOLYSIS; PATHOLOGY; PEDIATRICS; PHYSIOLOGY; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SEX DIFFERENCE; TREATMENT RESPONSE; URINALYSIS; VELOCITY;

BIOLOGICAL MARKERS; BONE DEVELOPMENT; BONE RESORPTION; CHILD; HUMANS; PEDIATRICS; REFERENCE VALUES;

EID: 33745203732     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2005.11.015     Document Type: Review

References (61)

1. Calvo M.S., Eyre D.R., and Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17 (1996) 333-368
2. Szule P., Seeman E., and Delmas P.D. Biochemical measurements of bone turnover in children and adolescents. Osteoporos. Int. 11 (2000) 281-294
3. Schoenau E., and Fauch S. Biochemical measurement of bone metabolism in childhood and adolescence. J. Lab. Med. 27 (2003) 32-42
4. Barera G., Beccio S., Proverbio M.C., and Mora S. Longitudinal changes in bone metabolism and bone mineral content in children with celiac disease during consumption of a gluten-free diet. Am. J. Clin. Nutr. 79 (2004) 148-154
5. Tobiume H., Kanzaki S., Hida S., et al. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J. Clin. Endocrinol. Metab. 82 (1997) 2056-2061
6. Posen S., and Grunstein H.S. Turnover rate of skeletal alkaline phosphatase in humans. Clin. Chem. 28 1 (1982) 153-154
7. Farley J.R., Hall S.L., Herring S., Libanati C., and Wergedal J.E. Reference standards for quantification of skeletal alkaline phosphatase activity in serum by heat inactivation and lectin precipitation. Clin. Chem. 39 (1993) 1878-1884
8. Chamberlain B., Buttery J., and Pannall P. A simple electrophoretic method for separating elevated liver and bone alkaline phosphatase isoenzymes in plasma after neuraminidase treatment. Clin. Chim. Acta 208 (1992) 219-224
9. Behr W., and Bernert J. Quantification of bone alkaline phosphatase in serum by precipitation with wheat germ lectin: a simplified method and its clinical plausibility. Clin. Chim. Acta 226 (1994) 143-150
10. Rosalki S.B., and Foo A.Y. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin. Chem. 30 (1984) 1182-1186
11. Magmusson P., Hager A., and Larsson L. Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr. Res. 38 (1995) 955-961
12. Blumsohn A., Hannon R.A., Wrate R., et al. Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. 40 (1994) 663-670
13. Robey P.A., and Termine J.D. Biochemical markers of metabolic bone disease. In: Avioli L.V., and Krane S.M. (Eds). Metabolic bone disease. 2nd ed. (1990), WB Saunders, Philadelphia 244-263
14. Crofton P.M., Shrivastava A., Wade J.C., et al. Bone and collagen markers in preterm infants: relationship with growth and bone mineral content over the first 10 weeks of life. Pediatr. Res. 46 (1999) 581-587
15. van Coeverden S.C.C.M., Netelenbos J.C., de Ridder C.M., Roos J.C., Popp-Snijders C., and Delemarre-van de Waal H.A. Bone metabolism markers and bone mass in healthy puberty boys and girls. Clin. Endocrinol. 57 (2002) 107-116
16. Nielsen H.K., Jorgensen J.O.L., Brixen K., Moller N., Charles P., and Christensen J.S. 24 h profile of serum osteocalcin in growth hormone (GH) deficient patients with and without GH treatment. Growth Regul. 1 (1991) 153-159
17. Delmas P.D., Chatelain P., Malaval L., and Bonne G. Serum bone Gla-protein in growth hormone deficient children. J. Bone Miner. Res. 4 (1986) 333-338
18. Johansen J.S., Jensen S.B., Riis B.J., Rasmussen L., Zachmann M., and Christiansen C. Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. J. Clin. Endocrinol. Metab. 71 (1990) 122-126
19. Heuck C., Skjaerbaek C., and Wolthers O.D. Diurnal rhythm of serum osteocalcin in normal children. Acta Paediatr. 87 (1998) 930-932
20. Banfi G., and Daverio R. In vitro stability of osteocalcin. Clin. Chem. 40 (1994) 833-834
21. Garnero P., Grimaux M., Seguin P., and Delmas P.D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9 (1994) 255-264
22. Power M.J., O'Dwyer B., Breen E., and Fottrell P.F. Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin. Chem. 37 (1991) 281-284
23. Fricke O., Stabrey A., and Schonau E. Chemiluminescence immunometric assay for measuring osteocalcin in healthy children. Clin. Lab. 46 (2000) 281-284
24. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., and Delmas P.D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J. Bone Miner. Res. 7 (1992) 1389-1398
25. Monaghan D.A., Power M.J., and Fottrell P.F. Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin. Clin. Chem. 39 (1993) 942-947
26. Cioffi M., Molinari A.M., Gazzerro P., et al. Serum osteocalcin in 1634 healthy children. Clin. Chem. 43 (1997) 543-545
27. Oginni L.M., Worsfold M., Sharp C.A., Oyelami O.A., Powell D.E., and Davie M.W. Plasma osteocalcin in healthy Nigerian children and in children with calcium-deficiency rickets. Calcif. Tissue Int. 59 (1996) 424-427
28. Lieuw-A-Fa M., Sierra R.I., and Specker B.L. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J. Bone Miner. Res. 10 (1995) 849-853
29. Saggese G., Baroncelli G.I., Bertelloni S., Cinquanta L., and Di Nero G. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J. Pediatr. 122 (1993) 37-45
30. Hassager C., Risteli J., Risteli L., Jensen S.B., and Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 7 (1992) 1307-1311
31. Melkko J., Niemi S., Risteli L., and Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36 (1990) 1328-1332
32. Pedersen B.J., and Bonde M. Purification of human procollagen type I carboxyl-terminal propeptide cleaved as in vivo from procollagen and used to calibrate a radioimmunoassay of the propeptide. Clin. Chem. 40 (1994) 811-816
33. Saggese G., Bertelloni S., Baroncelli G.I., and Di Nero G. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur. J. Pediatr. 151 (1992) 764-768
34. Rosenquist C., Fledelius C., Christgau S., et al. Serum CrossLaps one step ELISA: first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 44 (1998) 2281-2289
35. Watts N.B. Clinical utility of biochemical markers of bone remodeling. Clin. Chem. 45 (1999) 1359-1368
36. Rauch F., Schonau E., Woitge H., Remer T., and Seibel M. Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp. Clin. Endocrinol. 102 (1994) 94-97
37. Marowska J., Kobylinska M., Lukaszkiewicz J., Talajko A., Rymkiewicz-Kluczynska B., and Lorenc R.S. Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone 19 (1996) 669-677
38. Eyre D.R., Koob T.J., and Van Ness K.P. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal. Biochem. 137 (1984) 380-388
39. Black D., Duncan A., and Robins S.P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal. Biochem. 169 (1988) 197-203
40. Daniloff G.Y., Hesley R.P., Ju J., Evans B.J., and Seyedin S.M. An immunoassay for deoxypyridinoline. A highly specific marker of bone resorption. J. Bone Miner. Res. 8 (1993) S357 [abstract]
41. Robins S.P., Woitge H., Hesley R., Ju J., Seyedin S., and Seibel M.J. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9 (1994) 1643-1649
42. Rosano T.G., Peaston R.T., Bone H.G., Woitge H.W., Francis R.M., and Seibel M.J. Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation. Clin. Chem. 44 (1998) 2126-2132
43. Colwell A., Eastell R., Assiri A.M.A., and Russel R.G.G. Effect of diet on deoxypyridinoline excretion. In: Christiansen C., and Overgaard K. (Eds). Osteoporosis (1990), Osteopress ApS, Copenhagen 590-591
44. Fujimoto S., Kubo T., Tanaka H., Miura M., and Seino Y. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 80 (1995) 1922-1928
45. Vesper H.W., Demers L.M., Eastell R., et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin. Chem. 48 (2002) 220-235
46. Colwell A., Russell R.G., and Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur. J. Clin. Invest. 23 (1993) 341-349
47. Beardsworth L.J., Eyre D.R., and Dickson I.R. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J. Bone Miner. Res. 5 (1990) 671-676
48. Gerrits M.I., Thijssen J.H., and van Rijn H.J. Determination of pyridinoline and deoxypyridinoline in urine, with special attention to retaining their stability. Clin. Chem. 41 (1995) 571-574
49. Hanson D.A., Weis M.A.E., Bollen A.-M., Maslan S.L., Singer F.R., and Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7 (1992) 1251-1258
50. Mora S., Prinster C., Proverbio M.C., et al. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif. Tissue Int. 63 (1998) 369-374
51. Lehtonen-veromaa M., Mottonen T., Irjala K., Nuotio I., Leino A., and Viikari J. A 1-year prospective study on the relationship between physical activity, markers of bone metabolism, and bone acquisition in peripubertal girls. J. Clin. Endocrinol. Metab. 85 (2000) 3726-3732
52. Crofton P.M., Wade J.C., Taylor M.R., and Holland C.V. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin. Chem. 43 (1997) 1577-1581
53. Crofton P.M., Evans N., Taylor M.R., and Holland C.V. Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin. Chem. 48 (2002) 671-673
54. Mora S., Cella D., Puzzovio M., Cairella R., and Chiumello G. Radioimmunoassay for a new bone resorption marker and results for pediatric subjects. Clin. Chem. 39 (1993) 1745-1747
55. Prockop D.J., and Sjoerdsma A. Significance of urinary hyfroxyproline in man. J. Clin. Invest. 40 (1961) 843-849
56. Mautalen C.A., and Casco C. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. J. Lab. Clin. Med. 75 (1970) 11-18
57. Moro L., Modricky C., Rovis L., and de Bernard B. Determination of galactosyl hydroxylysine in urine as a means for the identification of osteoporotic women. Bone Miner. 3 (1988) 271-276
58. Moro L., Gazzarrini C., Modricky C., Rovis L., de Bernard B., et al. High predictivity of galactosyl-hydroxylysine in urine as an indicator of bone metastases from breast cancer. Clin. Chem. 36 (1990) 772-774
59. Moro L., Gazzarrini C., Crivellari D., Galligioni E., Talamini R., and de Bernard B. Biochemical markers for detecting bone metastases in patients with breast cancer. Clin. Chem. 39 (1993) 131-134
60. Rauch F., Schnabel D., Seibel M.J., et al. Urinary excretion of galactosyl-hydroxylysine is a marker of growth in children. J. Clin. Endocrinol. Metab. 80 (1995) 1295-1300
61. Rauch F., Georg M., Stabrey A., et al. Collagen markers deoxypyridinoline and hydroxylysine glycosides: pediatric reference data and use for growth prediction in growth hormone-deficient children. Clin. Chem. 48 (2002) 315-322